Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors
| Status: | Archived |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | January 2009 |
| End Date: | January 2011 |
Phase I Multicenter, Open-label, Dose-escalating Clinical and Pharmacokinetic Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors
Phase I multicenter, open-label, dose-escalating clinical and pharmacokinetic trial of
PM02734 administered in combination with erlotinib to determine the safety and tolerability
and to identify the dose limiting toxicity (DLT) and the recommended dose (RD) of the
combination of PM02734 and erlotinib, in patients with advanced malignant solid tumors.
Phase I multicenter, open-label, dose-escalating clinical and pharmacokinetic trial of
PM02734 administered in combination with erlotinib to determine the safety and tolerability
and to identify the dose limiting toxicity (DLT) and the recommended dose (RD) of the
combination of PM02734 and erlotinib, determine the preliminary pharmacokinetics (PK) of the
combination, evaluate the preliminary PK/pharmacodynamic correlation, evaluate the
preliminary antitumor activity, perform a preliminary pharmacogenomic (PGx) study to explore
molecular predictors of response to ErbB receptor antagonists and PM02734 in patient with
advanced malignant solid tumors.
We found this trial at
1
site
Montefiore Medical Center As the academic medical center and University Hospital for Albert Einstein College...
Click here to add this to my saved trials
